Royalty Pharma's total assets for Q1 2024 were $16.13B, a decrease of -1.53% from the previous quarter. RPRX total liabilities were $6.27B for the fiscal quarter, a -0.48% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.